Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel
Current Status: Open
Phase: N/A (Cancer Control)
Principal Investigator: Lunning, Matthew
The objective of this study is to provide access to axicabtagene ciloleucel that is OOS for commercial release to subjects with an approved labeled indication. The outcome measure is: - Incidence of SAEs and deaths from informed consent to 30 days post infusion or early withdrawal.